PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Estradiol - Menopausal disorders

PAD Profile : Estradiol - Menopausal disorders

Keywords :
hormone replacement therapy, HRT, menopause, unopposed oestrogen, menopausal symptoms
Brand Names Include :
Elleste Solo, Estraderm MX patch, Estradot Patch, Evorel Patch, FemSeven Patch, Lenzetto spray, Oestrogel, Progynova, Progynova TS patch, Sandrena gel, Zumenon

Traffic Light Status

Status 1 of 5.

Status :
Green
Important Preferred
Formulations :
  • Tablets
Important Information :
Elleste Solo tablets - 1st line
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Status 2 of 5.

Status :
Green
Important
Formulations :
  • Patches
Important Information :
Estradiol patches 2nd line to tablets. No preferred patch recommendation has been made due to current stock shortages (Estraderm, Estradot, Evorel, FemSeven, Progynova TS)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Status 3 of 5.

Status :
Green
Important
Formulations :
  • Spray
Important Information :
Lenzetto spray. Caution with higher than licensed doses.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :
Type
Document
Review Date
Evidence Review
Estradiol (transdermal spray) - Evaluation Pack - April 2022.pdf
Evidence Review
Estradiol (transdermal spray) - Formulary extension - April 2022.pdf

Status 4 of 5.

Status :
Green (see narrative)
Important
Formulations :
  • Gel
Important Information :
Oestrogel is the preferred gel option. Sandrena is an alternative option.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Status 5 of 5.

Status :
Green (see narrative)
Important
Formulations :
  • Tablets
Important Information :
Progynova and Zumenon tablets NOT 1st line. Only prescribe where Elleste Solo tablets are unavailable.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Webpage
NHS Hormone Replacement Therapy Prescription Prepayment Certificate (HRT PPC)
Webpage
NICE NG23 menopause-diagnosis-and-management

Committee Recommendations

Date
Committee Name
Narrative
03 July 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC has agreed a traffic light status and place in therapy for the treatments of menopausal disorders in line with the CKS recommenations:

Menopause | Health topics A to Z | CKS | NICE

06 April 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

LENZETTO - estradiol transdermal spray:

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends Lenzetto® transdermal spray as a treatment option in the treatment of menopause

Lenzetto® will be considered GREEN on the traffic light system. 

Patients who may be switched to Lenzetto® for the duration of the product shortages would then have the option of remaining on Lenzetto® or reverting to their previous formulation.

Associated BNF Codes

06. Endocrine System
06.04.01. Female sex hormones and their modulators
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More